GET DAILY SIGNALSTrulieve Cannabis (TRLV) vs cbdMD (YCBD): Weighing Scale Against Turnaround Potential
Key Takeaways
- Tickeron AI Verdict: Trulieve Cannabis Corp. (TRLV) is the favored ticker of the two, reflecting more consistent trend structure, stronger scale, and more clearly defined near-term catalysts relative to cbdMD, Inc. (YCBD).
- Both companies operate in the cannabis and hemp-adjacent space but sit at opposite ends of the spectrum: TRLV is a large, vertically integrated multi-state operator, while YCBD is a small-cap CBD and wellness brand portfolio.
- Recent market positioning favors TRLV, which has paired operational scale with balance-sheet improvements, whereas YCBD is pursuing an acquisition-driven diversification strategy with higher execution risk.
- For more detail on each name, explore TRLV Major News and TRLV Today's Price Move, as well as YCBD Major News and YCBD Today's Price Move.
- To see how AI evaluates opportunities like this one across the broader market, visit the curated Trending AI Robots page.
Setting the Scene: Two Different Paths in Cannabis
Investors comparing TRLV and YCBD are weighing two very different ways to gain exposure to the evolving cannabis and hemp market. Trulieve Cannabis Corp. is a large, vertically integrated multi-state operator (MSO) with a national retail footprint, while cbdMD, Inc. is a small-cap wellness company focused on CBD (cannabidiol) products and, more recently, nutritional supplements. This stock comparison is most relevant for traders and investors evaluating scale versus turnaround potential, balance-sheet strength versus speculative growth, and how differing business models translate into relative performance and market positioning in the current environment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Trulieve's Position and Recent Moves
Trulieve Cannabis Corp. (TRLV) is a vertically integrated, U.S.-focused medical cannabis operator with a dominant presence in Florida and additional operations in Georgia, Pennsylvania, and West Virginia. The company operates roughly 207 retail dispensaries alongside approximately 3.5 million square feet of cultivation and processing capacity, making it one of the largest MSOs by footprint.
In recent weeks, sentiment around TRLV has been supported by several balance-sheet and operational milestones. The company announced the full repayment of an approximately $65 million debt obligation and authorized a share repurchase program of up to $50 million. Its listing on the New York Stock Exchange—a notable step for a U.S. cannabis operator—has also improved its visibility and liquidity profile. These developments, combined with a track record of generating operating profit and positive free cash flow at scale, have contributed to a comparatively steadier market posture than smaller peers in the sector.
cbdMD's Strategy and Current Standing
cbdMD, Inc. (YCBD) is a wellness company headquartered in Charlotte, North Carolina, with a brand portfolio spanning CBD products (cbdMD, Paw CBD, Bluebird Botanicals), functional mushrooms (ATRx), and hemp-derived THC beverages (Oasis). It distributes through direct-to-consumer, e-commerce, and wholesale channels.
Recent market activity for YCBD has centered on its diversification strategy. The company completed the acquisition of the operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and ResVitale, expanding beyond hemp into vitamins, sports nutrition, and longevity supplements. While management has pointed to sequential revenue growth and improved liquidity, the company remains smaller in scale, with trailing revenue of roughly $21 million and a negative net income profile. These characteristics make YCBD more sensitive to integration risk, regulatory developments, and short-term sentiment shifts.
Side-by-Side Analysis
The contrast between these two companies is primarily one of scale and business model. TRLV is a vertically integrated operator controlling cultivation, processing, and retail, which supports higher revenue, operating profit, and free cash flow. YCBD, by comparison, is an asset-light brand and e-commerce platform with far smaller revenue and negative net income, but with an acquisition-led path toward diversification.
Growth drivers also diverge. TRLV is positioned around regulatory progress, footprint expansion, and capital-return initiatives. YCBD is focused on integration of newly acquired supplement brands and category expansion. Risk factors differ accordingly: TRLV faces sector-level regulatory and tax-related uncertainty, while YCBD carries added execution, financing, and small-cap volatility risks. From a sentiment standpoint, TRLV has exhibited relatively more stable market positioning, while YCBD has shown wider price swings consistent with its smaller market capitalization and transformative M&A (mergers and acquisitions) activity. One thing that stands out here is how the AI Trend Prediction Engine flagged these divergences early.
AI Assessment: Why TRLV Stands Out
Based on observable factors such as trend consistency, financial stability, scale, and the clarity of near-term catalysts, Tickeron's AI would likely favor TRLV over YCBD at this time. TRLV's larger revenue base, positive operating results, debt reduction, share repurchase authorization, and major-exchange listing present a comparatively steadier profile. YCBD offers a more speculative, acquisition-driven growth narrative with meaningful execution and regulatory uncertainty. In probabilistic terms, the AI assessment leans toward TRLV as the more favorably positioned ticker of the two, though both remain subject to sector-wide volatility.
Using Tickeron’s AI Trading Bots for Deeper Insights
In my own research process, Tickeron’s AI Trading Bots have been a practical way to test how different strategies might align with names like these. The platform lets users review performance metrics across hundreds of bots, compare win rates and holding periods, and match approaches to personal objectives without needing to build everything from scratch. It has helped me quickly narrow focus when sector conditions shift.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
YCBD's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for YCBD turned positive on October 21, 2026. Looking at past instances where YCBD's MACD turned positive, the stock continued to rise in 32 of 38 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where YCBD's RSI Oscillator exited the oversold zone, 30 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on YCBD as a result. In 86 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +9.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where YCBD advanced for three days, in 148 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 33 cases where YCBD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where YCBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
YCBD broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for YCBD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.568) is normal, around the industry mean (7.254). P/E Ratio (1.809) is within average values for comparable stocks, (0.575). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. YCBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YCBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of beauty shops
Industry PharmaceuticalsGeneric
Advertisement